RESUMEN
A randomized, double-blind clinical trial was conducted to investigate long-term abuse effects of testosterone cypionate (TC). Thirty-one healthy men were randomized into a dose group of 100, 250, or 500 mg/wk and received 14 weekly injections of TC. A pharmacokinetic/pharmacodynamic (PK/PD) model was developed to characterize testosterone concentrations and link exposure to change in luteinizing hormone and spermatogenesis following long-term TC administration. A linear one-compartment model best described the concentration-time profile of total testosterone. The population mean estimates for testosterone were 2.6 kL/day for clearance and 14.4 kL for volume of distribution. Weight, albumin, and their changes from baseline were identified as significant covariates for testosterone. The estimated potency of total testosterone (tT) with respect to suppression of luteinizing hormone (LH) synthesis was 9.33 ng/mL. Simulation based on the indirect response model suggests the suppression of endogenous testosterone secretion, LH synthesis, and spermatogenesis was more severe and of greater duration in the 250 mg and the 500 mg dose groups.
Asunto(s)
Anabolizantes/farmacología , Andrógenos/farmacología , Modelos Biológicos , Testosterona/análogos & derivados , Adulto , Anabolizantes/administración & dosificación , Anabolizantes/sangre , Andrógenos/administración & dosificación , Andrógenos/sangre , Método Doble Ciego , Voluntarios Sanos , Humanos , Hormona Luteinizante/sangre , Masculino , Espermatogénesis/efectos de los fármacos , Testosterona/administración & dosificación , Testosterona/sangre , Testosterona/farmacología , Adulto JovenRESUMEN
BACKGROUND: Lithium was the first clinically effective mood stabilizer marketed worldwide. However, the medical literature suggests that lithium may have an indication as a neuroprotective agent. METHODS: This review discusses the pharmacologic activity and potential effectiveness of lithium in the context of Alzheimer disease (AD) and Parkinson's disease (PD), the 2 most prominent neurodegenerative disorders in the United States. The toxicities of lithium, including lithium-induced extrapyramidal symptoms (LI-EPS) and cognitive impairments at therapeutic blood levels, are discussed. Cases that are thought to illustrate LI-EPS and cognitive impairments are critiqued. RESULTS: Animal studies have shown positive results regarding the neuroprotective and antioxidant properties of lithium. Human studies indicate a potential benefit of lithium for improving cognition. Ongoing replicative studies are attempting to confirm the effectiveness and efficacy of lithium for treating patients diagnosed with AD or PD. CONCLUSIONS: The available medical literature supports the conclusion that lithium should be considered as a research candidate medication for the treatment of neurologic diseases of dementias and PD.